VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EMN 2021 | Pomalidomide plus dexamethasone for R/R multiple myeloma

Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, gives an overview of the results of a retrospective analysis of pomalidomide and dexamethasone therapy for patients with relapsed/refractory (R/R) multiple myeloma. The study analyzed data from 57 patients with R/R multiple myeloma who were treated with pomalidomide plus dexamethasone. The study found that pomalidomide was well tolerated with an overall response rate of 47.3%. Five patients achieved a complete response and 11 patients achieved a very good partial response. The median overall survival from the start of pomalidomide therapy was nine months. This interview took place during the 2021 European Myeloma Network (EMN) congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter